Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naproxen sodium/sumatriptan - Old API Wind-down

Drug Profile

Naproxen sodium/sumatriptan - Old API Wind-down

Alternative Names: MT-400; Naproxen sodium/sumatriptan succinate; SumaRT/Nap; Sumatriptan/naproxen sodium; Suvexx; Trexima; Treximet

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; POZEN
  • Developer Currax Pharmaceuticals; Miravo Healthcare; Old API Wind-down Ltd
  • Class Anti-inflammatories; Antimigraines; Indoles; Naphthaleneacetic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Sulfonamides; Tryptamines
  • Mechanism of Action 5-HT1 serotonin receptor agonists; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 15 Aug 2023 Launched for Migraine in Estonia, Lithuania, Latvia, Hungary, Poland, Norway, Denmark, Sweden, Finland (PO)
  • 15 Aug 2023 Naproxen sodium/sumatriptan licensed to Orion for the exclusive right to package, distribute, market and sell, in all remaining European Union countries outside of the original License Agreement Territory
  • 15 Aug 2023 Orion announces intention to launch Naproxen sodium/sumatriptan for Migrain in Austria, Belgium, the Czech Republic, France, Germany, Greece, Ireland, Italy, the Netherlands, Portugal, Slovakia, Spain, Switzerland and the UK
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top